vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$17.10 USD
-0.50 (-2.84%)
Updated Jun 7, 2024 03:24 PM ET
After-Market: $17.07 -0.03 (-0.18%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
vTv Therapeutics Inc. [VTVT]
Reports for Purchase
Showing records 21 - 40 ( 44 total )
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
TTP399 Is Simply the Main Part of the Story Until Azeliragon Data in Late 2020; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Initiates Phase 2 Trial With Azeliragon in Mild Alzheimer''s and Type 2 Diabetes
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
More Than a Sliver of Improvement Shown by Positive Topline
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
How to Move Beyond the Amyloid Hypothesis in Alzheimer?s Disease; Initiating With a Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of VTVT due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Maintaining Neutral After Part B Fails To Meet Trial Co-Endpoints
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Analysis of STEADFAST Trial Part A Shows Efficacy in Patient Sub-group
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Lowering to Neutral as Phase III Fails to Meet Co-Primary Endpoints
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We''re on the Edge of Our Seats Waiting for STEADFAST Data
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We Are Initiating Coverage
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Companies with Novel Approaches to Alzheimer''s Disease
Provider: Roth Capital Partners, Inc.
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
RAGE Is Building With Phase 3 Alzheimer''s Data Set for 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
STEADFAST Enrolling Quicker Than Anticipated Amidst Hunt for a Deal in Cutthroat Diabetes Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: vTv Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
TTP399 Phase 2b Poster at ENDO Offers Greater Detail on Last Year''s Positive Data in Diabetes
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C